_PRIVATE_LIMITED_386824.webp)
Humanbiologics Products And Services (Opc) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 164.86%
(FY 2022)
- Profit 85.85%
(FY 2022)
- Ebitda 2084.22%
(FY 2022)
- Net Worth 133.88%
(FY 2022)
- Total Assets -44.00%
(FY 2022)
About Humanbiologics Products And Services (Opc)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chetan Sharma serves as a director at the Company.
- CIN/LLPIN
U24100UP2017OPC095354
- Company No.
095354
- Incorporation Date
25 Jul 2017
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Humanbiologics Products And Services (Opc) Private Limited offer?
Humanbiologics Products And Services (Opc) Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Patient Monitoring System, Face Mask & Medical PPE Kits, Disposable Gloves, Oxygen Concentrator.
Who are the key members and board of directors at Humanbiologics Products And Services (Opc)?
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetan Sharma  | Director | 25-Jul-2017 | Current |
Financial Performance of Humanbiologics Products And Services (Opc).
Humanbiologics Products And Services (Opc) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 164.86% increase. The company also saw a substantial improvement in profitability, with a 85.85% increase in profit. The company's net worth Soared by an impressive increase of 133.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Humanbiologics Products And Services (Opc)?
In 2022, Humanbiologics Products And Services (Opc) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Humanbiologics Products And Services (Opc)?
Unlock and access historical data on people associated with Humanbiologics Products And Services (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Humanbiologics Products And Services (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Humanbiologics Products And Services (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
